Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569313 | 0.95 | MAPT (0.51) | MAPTALDH1A1MAPK1GAAUSP2 | |
| SCHEMBL2568313 | 0.92 | ALDH1A1 (0.43) | MAPTALDH1A1MAPK1LMNAKMT2A | |
| SCHEMBL2570915 | 0.90 | MAPT (0.45) | MAPTALDH1A1MAPK1GAALMNA | |
| SCHEMBL2568639 | 0.90 | WNT3A (0.43) | MAPTALDH1A1MAPK1GAAUSP2 | |
| SCHEMBL2565831 | 0.89 | POLB (0.46) | MAPTALDH1A1GAAPOLB | |
| SCHEMBL2568344 | 0.88 | MAPT (0.56) | MAPTALDH1A1MAPK1LMNAUSP2 | |
| SCHEMBL2565909 | 0.87 | POLB (0.47) | MAPTALDH1A1GAAKDM4EPOLB | |
| SCHEMBL2568309 | 0.86 | MAPT (0.47) | MAPTALDH1A1MAPK1USP2KMT2A | |
| SCHEMBL2564993 | 0.85 | MEN1 (0.41) | MAPTALDH1A1GAAKMT2AKDM4E | |
| SCHEMBL2568171 | 0.85 | GAA (0.51) | MAPTALDH1A1MAPK1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | claimed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | claimed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | claimed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | MAPT 2195/4885ALDH1A1 1535/4885MAPK1 3311/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | MAPT 2195/4885ALDH1A1 1535/4885MAPK1 3311/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | MAPT 2195/4885ALDH1A1 1535/4885MAPK1 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.